On a consolidated basis, the drug maker's net profit jumped 18.3% to Rs 297 crore on a 2.5% increase in net sales at Rs 1,972 crore in Q3 December 2020 over Q3 December 2019. Total revenues rose 1% to Rs 1,995 crore in Q3 FY21 as against Rs 1,966 crore in Q3 FY20. Gross margins were at 72% and operating EBITDA margins were at 30%. Profit before tax (PBT) surged 11.9% to Rs 357 crore in Q3 December 2020 as against Rs 319 crore in Q3 December 2019. Tax expense for the quarter soared 11.9% to Rs 75 crore as against Rs 67 crore paid in Q3 December 2019. The Q3 result was declared after market ho...